Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07072793 · ClinicalTrials.gov registry record
A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 131,005
- Enrollment target
NCT07072793 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 131,005 participants.
The verdict
NCT07072793 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 131,005 participants
- Enrollment target
Study Summary
The purpose of this study is to understand how COVID-19 affects people's ability to work and to calculate the costs associated with loss of work. The study compares two groups of participants who are confirmed to have mild-to moderated COVID-19 and who have high chances of the disease becoming severe. The two groups are: People who took the antiviral medication nirmatrelvir-ritonavir (also called Paxlovid) People who were eligible to receive antiviral medication but did not receive any. The participants will be selected from various health databases in the US between June 2021 and December 2022. The main goals are: To look at the characteristics of both groups of participants with COVID-19. To measure how much work these participants missed, including days off and sick leave, and the costs associated with this work loss. To compare work loss and costs between the two groups of participants, considering differences in their clinical and demographic characteristics. The study will evaluate at least 30 days of data from participants after they are confirmed to have COVID-19
Interventions
- DRUG nirmatrelvir-ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131,005 participants |
| Start Date | 2024-10-31 |
| Est. Completion | 2024-11-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07072793
The ClinicalTrials.gov registry entry for NCT07072793 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 131,005 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nirmatrelvir-ritonavir is the first listed.
NCT07072793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07072793 about?
NCT07072793 is a clinical study titled "A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe". The purpose of this study is to understand how COVID-19 affects people's ability to work and to calculate the costs associated with loss of work. The study compares two groups of participants who are confirmed to have mild-to moderated COVID-19 and who have high chances of the disease becoming seve...
What is the current status of trial NCT07072793?
This trial is currently completed. The enrollment target is 131,005 participants. The study started on 2024-10-31. Estimated completion is 2024-11-15.
What interventions are being tested in trial NCT07072793?
The interventions under investigation include: nirmatrelvir-ritonavir (DRUG).
Who is sponsoring clinical trial NCT07072793?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.